Work

Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps4597

Authors: Brian I. Rini, Thomas Powles, Mei Chen, Markus Puhlmann, Michael B. Atkins

Institutions: Cleveland Clinic, Barts Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), Georgetown University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2748036232

Cites:

Cited by: 15

Related to: 10